Search
Hengrui Medicine Receives Approval for Clinical Trial of HRS-4729 Injection
4 day ago /
Read about 0 minute
Author：小编
Hengrui Medicine, along with its subsidiary Fujian Shengdi Pharmaceutical, has recently been granted the "Drug Clinical Trial Approval Notice" by the National Medical Products Administration for HRS-4729 Injection. HRS-4729, a peptide drug independently developed by the company, serves as a triple agonist, and clinical trials are set to commence in the near future.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
